Schedule

The ACCP Updates in Therapeutics®: Pharmacotherapy Preparatory Review and Recertification Course will be held Saturday and Sunday, April 27-28, 2019.

Click below for the full meeting schedule.

Updates in Therapeutics® 2019 Preparatory
Review and Recertification Courses
April 27-28, 2019


Pharmacotherapy Preparatory Review and Recertification Course -- Infectious Diseases, HIV/Infectious Diseases, Pediatrics, and Anticoagulation

Sunday, April 28, 2019 from 8:00 AM to 12:30 PM CDT at Academic and Research Building: First and Second Floors, Auditorium

Available for 3.75 hours of CPE credit
Activity Number: 0217-0000-19-075-L01-P

Infectious Diseases
7:45 AM to 8:45 AM
Academic and Research Building: Auditorium

Speakers
Speaker: Curtis L. Smith, Pharm.D., BCPS
Professor, Ferris State University, Lansing, Michigan
View Biography
Curtis L. Smith, Pharm.D., BCPS
Smith
Infectious Diseases
8:00 AM to 9:00 AM
Academic and Research Building: First and Second Floors, Auditorium

Learning Objectives
1. Identify the presenting signs and symptoms, etiology, and risk factors of respiratory tract infections, urinary tract infections, skin and soft tissue infections, osteomyelitis, central nervous system (CNS) infections, intra-abdominal infections, Clostridioides difficile infections, and endocarditis.
2. Recommend appropriate treatment for patients with respiratory tract infections, urinary tract infections, skin and soft tissue infections, osteomyelitis, CNS infections, intra-abdominal infections, C. difficile infections, and endocarditis.
3. Select appropriate preventive therapy for CNS infections, endocarditis, and surgical wound infections.
HIV/Infectious Diseases
9:00 AM to 10:00 AM
Academic and Research Building: First and Second Floors, Auditorium

Speakers
Speaker: Curtis L. Smith, Pharm.D., BCPS
Professor, Ferris State University, Lansing, Michigan
View Biography
Curtis L. Smith, Pharm.D., BCPS
Smith

Learning Objectives
1. Formulate an appropriate regimen to prevent or treat HIV infections, including initiating and monitoring therapy.
2. Discuss appropriate treatment of the various acquired immunodeficiency syndrome opportunistic infections, including primary and secondary prophylaxis.
3. Describe appropriate treatment and preventive therapy for tuberculosis, including infections with drug-resistant organisms.
4. Design appropriate therapeutic regimens for treating systemic and superficial fungal infections and classify the various antifungal agents.
Pediatrics
10:00 AM to 11:00 AM
Academic and Research Building: First and Second Floors, Auditorium

Speakers
Speaker: Deborah S. Bondi, Pharm.D., BCPS, BCPPS
‎Clinical Pharmacy Specialist - Neonatal Intensive Care Unit, University of Chicago Medicine, Comer Children's Hospital, Chicago, Illinois
View Biography
Deborah S. Bondi, Pharm.D., BCPS, BCPPS
Bondi

Learning Objectives
1. Recommend therapeutic options for the man¬agement of neonatal and pediatric sepsis and meningitis.
2. Identify the drugs available for preventing and treating respiratory syncytial virus and indications for use.
3. Explain the most common causative organisms of otitis media and potential treatment options.
4. Apply the recommended pediatric immuniza¬tion schedule and discuss barriers to routine immunization.
5. Examine the differences in anticonvulsant man¬agement, including pharmacokinetics and adverse effects, between children and adults.
6. Implement an appropriate treatment regimen for patients with attention-deficit/hyperactivity disorder.
Break
11:00 AM to 11:15 AM
Anticoagulation
11:15 AM to 12:30 PM
Academic and Research Building: First and Second Floors, Auditorium

Speakers
Speaker: Paul P. Dobesh, Pharm.D., FCCP, BCPS
Professor of Pharmacy Practice, College of Pharmacy University of Nebraska Medical Center, Omaha, Nebraska
View Biography
Paul P. Dobesh, Pharm.D., FCCP, BCPS
Dobesh

Learning Objectives
1. Recommend a patient-specific pharmacotherapy plan to reduce the risk of stroke in patients with nonvalvular atrial fibrillation.
2. Develop a feasible pharmacologic management plan to reduce thrombotic events in patients with different valvular diseases and different types of valves.
3. Devise an evidence-based pharmacotherapy plan for preventing and treating venous thromboembolism (VTE).
4. Analyze the need for anticoagulant therapy in patients with atrial fibrillation or VTE.
5. Determine appropriate reversal strategies for patients at risk of active bleeding, or actively bleeding while receiving oral anticoagulation therapy.
6. Determine appropriate selection and dosing of anticoagulant therapy on the basis of patient-specific factors and drug interactions.